SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia-related cytogenetics). 4 of those patients had myelomonocytic phenotype (M4 per FAB classification). The ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

The company announced that the trial's Cohort 3 results showed a median overall survival (mOS) of 8.9 months in patients with AML-myelodysplasia-related ... GPS in Acute Myeloid Leukemia without ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a ...

If your polycythemia vera turns into myelodysplastic syndrome (MDS), you now have ... For example, it's possible it can turn into acute myeloid leukemia (AML). One in three people with MDS will ...